key: cord-0917377-pncwj3m8
authors: Magro, Cynthia; Mulvey, J. Justin; Laurence, Jeffrey; Seshan, Surya; Crowson, A. Neil; Dannenberg, Andrew J.; Salvatore, Steven; Harp, Joanna; Nuovo, Gerard J.
title: Docked SARS CoV-2 Proteins within the Cutaneous and Subcutaneous Microvasculature and their Role in the Pathogenesis of Severe COVID-19
date: 2020-10-12
journal: Hum Pathol
DOI: 10.1016/j.humpath.2020.10.002
sha: b115349ad27ccc4fa685c18b8b25f4b7bcc617bd
doc_id: 917377
cord_uid: pncwj3m8

The purpose of this study was to examine the deltoid skin biopsy in twenty-three COVID-19 patients, most severely ill, for vascular complement deposition and correlate this with SARS CoV-2 viral RNA and protein localization and ACE2 expression. The deltoid skin microvascular complement screen has been applied to patients with various systemic complement-mediated microvascular syndromes best exemplified by atypical hemolytic uremic syndrome. In 21/23 cases, substantial microvascular deposition of complement components was identified. The two patients without significant complement deposition included one patient with moderate disease and a severely ill patient who although on a ventilator for a day was discharged after 3 days. The dominant microvascular complement immunoreactant identified was the terminal membranolytic attack complex C5b-9. Microvascular complement deposition strongly co-localized in situ with the SARS CoV-2 viral proteins including spike glycoproteins in the endothelial cells as well as the viral receptor ACE2 in lesional and non-lesional skin; viral RNA was not evident. Microvascular SARS CoV-2 viral protein, complement and ACE2 expression was most conspicuous in the subcutaneous fat. Although the samples from severely ill patients with COVID-19 were from grossly normal skin, light microscopically focal microvascular abnormalities were evident that included endothelial cell denudement, basement membrane zone reduplication and small thrombi. It is concluded that complement activation is common in grossly normal skin, primarily in the subcutaneous fat which may provide a link between severe disease and obesity, in people with severe COVID-19 and the strong co-localization with the ACE2 receptor and viral capsid proteins without viral RNA suggests that circulating viral proteins (i.e. pseudovirions) may dock onto the endothelial of these microvessels and induce complement activation.

We have recently demonstrated that complement-mediated microvascular injury is a critical feature that underlies the pathophysiology of severe COVID-19 and presented evidence that endocytosed spike glycoproteins of SARS-CoV-2 within endothelium result in the direct activation of the mannan binding lectin (MBL) complement pathway in the microvasculature of the lung and skin [1] . We showed that SARS CoV-2-induced acute respiratory failure is a microangiopathy targeting the septal capillary microvasculature whereby extensive microvascular deposits of C4d and C5b-9 suggest a causal association between complement deposition and vascular injury [1] .

Based on WHO classifications for mild, moderate, severe, and critical disease [2] (in this document critical and severe will be combined as "severe"), severe COVID-19 patients have evidence of other organ dysfunction related to complement-mediated and prothrombotic vascular disease such as stroke, hepatic failure, lower extremity arterial occlusion, and acute kidney injury (AKI) [3, 4] . In the skin, this pathobiology underlies the distinctive COVID-19 associated thrombotic retiform purpura, corresponding microscopically with a complement-mediated pauci-inflammatory thrombogenic vasculopathy [1, 5] .

A deltoid skin biopsy has been used to diagnose patients with other systemic complementmediated microvascular injury syndromes such as atypical hemolytic uremic syndrome (aHUS) and differentiate these disorders from thrombotic thrombocytopenic purpura associated with antibodies to ADAMSTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) [6] . This procedure has been performed at our institution to determine suitability for complement inhibition therapy with the humanized monoclonal antibody eculizumab which targets the terminal complement component C5.

In the initial pilot study of five COVID-19 cases [1] where complement-mediated vascular injury was seen in severe COVID-19 disease, we were able to document evidence of systemic J o u r n a l P r e -p r o o f complement activation using the deltoid biopsy in two patients. Since then, we have been utilizing the established normal skin biopsy protocol to identify ill patients who might benefit from complement inhibition therapy when refractory to other therapies.

This manuscript provides a detailed analysis of SARS CoV-2 viral protein, ACE2, SARS CoV-2 viral RNA and complement deposition patterns in skin from severe and fatal COVID-19

patients. The data suggest that circulating pseudovirions are endocytosed by ACE2+ endothelial cells in the skin's microvessels that can induce localized MBL complement activation and therefore defines a potential mechanism for distant microvascular and prothrombotic complications due to the interplay and amplification of MBL activation with the alternative complement pathway and coagulation cascade.

J o u r n a l P r e -p r o o f

The patient cohort (cases 1 through 23) included archival biopsy material of normal-appearing deltoid skin procured from 14 live patients who were significantly symptomatic with COVID-19 (cases 1 through 14) as well as 9 people who died of the disease. The normal skin biopsies were performed by the attending dermatologist at the request of the treating physician to establish evidence of systemic involvement of significant complement activation providing justification for use of eculizumab in those cases not responding to current therapy. Thirteen of these patients fulfilled the CDC criteria to be labelled as having severe COVID-19 while one patient was designated as having moderate COVID- 19 . The categorization as moderate and severe were based on criteria set forth by the World Health

Organization. Moderate COVID-19 is defined by an infected patient with fever and who is bed ridden exhibiting variable shortness of breath although not requiring intensive care hospitalization with ventilator support while patients falling into the severe COVID-19 category have organ failure typically the lung or kidney and require intensive care hospitalization. Three of these patients are part of a previously published study [1] . In each of the 23 cases there was confirmation of SARS CoV-2 infection with a positive nasopharyngeal swab for SARS CoV-2 RNA.

Also studied from a vascular complement deposition perspective were normal skin in pre-COVID patients not known to have systemic complement activation. Specifically, six grossly normal deltoid biopsies obtained from pre-COVID-19 era patients who had undergone the deltoid biopsy to rule-out aHUS were studied; each patient was found not to have aHUS based on the overall clinical presentation and laboratory parameters. Eight additional blocks of deltoid skin procured from routine re-excision specimens from the pre-COVID era were also assessed. Finally, skin samples taken for J o u r n a l P r e -p r o o f conditions unrelated to COVID-19 were obtained from four patients who were COVID-19 positive but without clinical features of moderate or severe COVID-19.

The samples were first examined by routine hematoxylin and eosin (H and E). The focus of the study was the evaluation of the vascular deposition of C5b-9, C3d, and C4d with SARS-CoV-2 localization. In some of the biopsies, we also assessed MBL associated serine protease2 (MASP2).

Significant C5b-9 deposition was defined as a vasocentric granular and or homogeneous pattern well above background at least of moderate intensity, typically in an endothelial and/or subendothelial location. An evidence-based cut off of fewer than 10 positive-staining vessels was not considered diagnostic of significant complement deposition. Other non-diagnostic patterns included C5b-9 deposits within the epidermal and eccrine coil basement membrane zone, the pilar erector muscle and dermal elastic fibers, the internal elastic lamina of vessels and elastic tissue around lymphatics. The other markers of complement were assessed by the same principles applied for C5b-9. The methodologies for C3d, C4d, and C5b-9 staining have been described in prior publications [7, 8] .

Immunohistochemical staining of C3d (Ready to use polyclonal antibody, Cell Marque), C4d (1:50, monoclonal antibody, Quidel), and C5b-9 (1:250, clone aE11, Dako) was accomplished using the Bond III Autostainer (Leica Microsystems, Illinois, USA). Formalin fixed and paraffin-embedded tissue sections were first baked and deparaffinized. Antigen retrieval was followed by heating the slides at 99-100°C in Bond Epitope Retrieval Solution 2 for 20 minutes (for C3d and C4d), and at 37°C in Bond Enzyme solution for 10 minutes (for C5b-9). Sections were then incubated sequentially with the primary antibody for 15 minutes, post-primary (equivalent to secondary antibody) for 8 minutes, polymer (equivalent to tertiary antibody) for 8 minutes, endogenous peroxidase block for 5 minutes, diaminobenzidine (DAB) for 10 minutes, and hematoxylin for 5 minutes. Bond Polymer Refine Detection was used for all three antibodies. The material reviewed for this study represents J o u r n a l P r e -p r o o f archival pathology material where any additional studies were covered under IRB protocol 20-02021524.

Detection of SARS-CoV-2 RNA was done using the ACD RNAscope probe (Cat No. 848561-C3) through a previously published protocol in which only the viral RNA probe is changed [12.13] . The SARS-CoV-2 probe targets the region nt 21631 -23303 derived from the genomic sequence of the virus (NC_045512.2). In brief, pretreatment in the ACD RNA retrieval solution and protease digestion is followed by overnight hybridization at 37 o C and detection using the ACD 2.5 HD diaminobenzidene (DAB) detection kit.

Our immunohistochemistry protocol for SARS-CoV-2 capsid proteins has been previously published [9, 12, 13] . In brief, the Leica Bond Max automated platform was used with the primary antibodies (ProSci Poway, CA) at dilutions of 1:250 (membrane), 1:4500 (spike) and 1:500 (envelope) after antigen retrieval for 30 minutes. The HRP conjugate from Enzo Life Sciences was used in place of the equivalent reagent from Leica as this has been shown to substantially reduce background [9] .

We also assessed ACE-2 expression using the primary antibody from Proteintech (1: 13,000 dilution, antigen retrieval for 30 minutes).

Co-expression analyses were done using the Nuance system whereby each chromogenic signal is separated, converted to a fluorescence based signal, and then mixed to determine if cells were expressing the two proteins of interest [9,10].

J o u r n a l P r e -p r o o f Electron microscopy was performed on deparaffinized tissue from deltoid skin in the routine manner using osmium tetroxide and stained with uranyl acetate and lead citrate. Ultrastructural photography was performed on a transmission electron microscope (TEM, HT-7800, Japan).

Six female and eight male patients diagnosed with moderate (n=1) or severe (n=13) COVID-19, with a positive RT-PCR assay for SARS-CoV-2, as performed by a designated laboratory, and ranging in age from 28 to 73 years, had skin biopsies taken from the deltoid region. These are shown as Cases 1-14 in Table 1 . Twelve of the 14 patients were in respiratory failure on a ventilator, though one patient (Case 8) was extubated 1 day after the biopsy was performed and was discharged to home 3 days later. One patient (Case 7) with sickle cell anemia developed AKI without respiratory failure, and 8 others also had AKI (Table 1) . One patient (Case 12) had significant respiratory symptoms but was not on a ventilator at the time of biopsy, nor did the patient subsequently become ventilatordependent or develop any acute organ failure. This patient fulfilled criteria to warrant categorization as being moderately ill with COVID-19. Six of the severely ill patients on ventilator support had livedoid skin rashes (cases 1 through 6) involving the extremities with prominent acral localization in 4 and the torso in 1 (Figure 1 : panel A) ( Table 1) Table 1 ) comprised 7 males and 2 females ranging in age from 34 years to 95 years. All patients died from SARS CoV-2 associated acute respiratory distress syndrome. Their clinical course was complicated by AKI in 4 of the 9 cases and acute liver injury in 1.

Their initial presentation at the hospital was one of cough, fever and progressive shortness of breath.

The time that lapsed between presentation at the hospital with admission and death ranged from 1 day J o u r n a l P r e -p r o o f to 3 weeks. Pre-existing conditions were seen in all including hypertension (6), hyperlipidemia (4), diabetes mellitus (4), coronary artery disease (2), chronic lung disease (2) , and malignancy(2) ( Table   1 ). The patient's BMIs ranged from 19.7 to 43 with an average BMI of 28.8; 4/9 patients were obese.

None of these patients had a skin rash.

While the dominant focus of this study was normal deltoid skin, in 6 of the cases there was a biopsy performed of the livedoid rash of COVID-19. The biopsied livedoid rash showed a pauciinflammatory thrombogenic vasculopathy affecting capillaries and both the venous and arterial systems. There was morphologic evidence of endothelial cell injury. The thrombotic diathesis was largely unaccompanied by significant inflammation. There were extensive vascular deposits involving capillaries and the venular and arterial system throughout the dermis and subcutaneous fat for C5b-9 ( Figure 1 : panels B, C and D, Figure 6 ), C3d and C4d.

Normal deltoid skin biopsies from 11/14 pre-mortem cases, including all 6 cases with biopsied livedoid rashes, showed significant deposits of C5b-9 within vessels especially vessels in the mid, deeper dermis and subcutaneous fat in excess of 10 positive staining vessels Vascular decoration for C4d, while positive in 12/14 cases, was significantly less in terms of number of positive vessels and intensity of decoration except in two cases where it exceeded vascular C5b-9 . C3d exhibited positive immunoreactivity in 8/14 cases, but was qualitatively and quantitatively less than that observed for C5b-9, except in 1 case.

In 11/14 cases, the vascular complement deposition was present in capillaries, venules and the arterial system. Two of the 3 cases without arterial complement decoration had less severe disease (case 8 and case 12).

In cases 8 and 12, the number of vessels expressing any of the complement components was not deemed to be significant as it was less than 10 vessels with a positive reaction. One had a moderate disease course and did not require ventilation at any point during her clinical course. Case 8 did not require prolonged ventilation.

MASP2, a marker of MBL pathway complement activation, was positive in 4/7 cases that were evaluated and exhibited an endothelial and intravascular deposition pattern (Figure 2: panel B) while it was negative in one patient without severe COVID-19 disease (case 8).

Fourteen of the 23 biopsies where tissue was available were tested for SARS CoV-2 viral RNA as well as the capsid proteins envelope, spike, and/or membrane using immunohistochemistry and compared to normal skin biopsies obtained prior to 2018 (n = 10); results were read blinded to the clinical information. In each of the severe COVID-19 cases represented by biopsies of thrombotic retiform purpura and normal appearing deltoid skin, viral protein was detected in microvessels especially in the mid to deep dermis and subcutaneous fat (Figure 2 panels A through D) . Each of the negative controls was negative for SARS-CoV-2 capsid proteins. Serial section analyses showed that the SARS-CoV-2 capsid proteins showed equivalent distributions including parallel microvascular expression pattern was noted for the spike glycoprotein (S) and membrane protein (M) of SARS-CoV-2 although spike glycoprotein expression was qualitatively and quantitatively less compared to viral capsid membrane and or envelope expression. Co-expression analyses also confirmed that the endothelial expression of the complement activated proteins co-localized with the viral capsid proteins in 3 cases tested ( Figure 5, panels A and B ).

Additional serial sections were then tested for SARS-CoV-2 RNA using in situ hybridization. All COVID-19 skin biopsies tested were negative for viral RNA, with strong positive controls from the lung tissues of people who died of COVID-19.

Since the receptor for SARS-CoV-2 is ACE-2, the skin biopsy cases and controls were tested for ACE2 by immunohistochemistry whereby a total of 15 cases were examined (10 study cases and 5 normal controls). Endothelial cells, especially in the lower dermis and subcutaneous fat, strongly 

None of the control specimens as outlined under the materials and methods showed significant deposition of C5b-9, C3d and or CD4 (i.e. less than 10 positive staining vessels). COVID-19 positive patients with mild or asymptomatic disease were negative for SARS CoV-2 viral protein as well as the normal pre-COVID controls.

To assess if there was any morphologic evidence that the complement deposition was associated with any subtle evidence of microvascular injury, the samples were carefully scrutinized for J o u r n a l P r e -p r o o f the type of small vessel injury that signifies complement-mediated injury. Primarily involving the deeper dermis and microvasculature of the fat, there was very focal endothelial cell denudement ( Figure 6, panel A) , basement membrane zone reduplication, aneurysmal dilatation of capillaries, and luminal thrombi (Figure 6, panel B) ; small foci of lipomembranous fat necrosis, presumably driven by local anoxia was also noted. The changes were similar to the septal microangiopathy of severe COVID-19 but were only discernible with very careful inspection and by examining the vessels under oil immersion.

One case of autopsy deltoid skin was examined ultrastructurally. A deep dermal capillary showed endothelial cell swelling, abundant rough endoplasmic reticulum, intracytoplasmic lysosomes, and microvesicular bodies representing a form of lysosomes that are associated with cellular injury. In addition there were a cluster of circular bodies with indistinct spike like projections emanating from the surface ranging from 45-55 nm in diameter, without a granular core (arrow heads) and found freely within the cytosol (Figure 7 ) consistent with pseudovirions. Intact virions were not identified.

It was recently shown that complement-mediated microvascular injury affecting the septal capillaries of the lung, and the capillary, venous and/or arterial microvasculature of the skin, defines a significant component of the underlying pathophysiology of severe COVID-19 [1, 5] . The systemic nature of COVID-19 is reinforced by the findings of thrombotic livedoid purpura in the earlier study [1] , and observed in three additional cases in this current study, along with additional reports detailing stroke and thrombotic emboli [3, 11] . In this study, patients with severe COVID-19 demonstrated significant microvascular complement deposition in both thrombosed lesional and normal appearing non-lesional skin and subcutaneous fat. The extent of vascular C5b-9 deposition in patients with severe COVID-19 was to a degree that has been shown in prior studies to signify systemic complement activation. Further, the microvascular complement deposition was accompanied by histologic features characteristic for complement-mediated microvascular injury such as endothelial cell denudement, basement membrane zone reduplication, and intravascular thrombi most apparent in the deeper dermis and subcutaneous fat where the microvascular complement deposition was greatest.

The presumed basis for this pattern of cutaneous vascular complement deposition and subsequent vascular injury is the ability of the SARS-CoV-2 to activate the complement pathway systemically. We postulate that the mechanism of complement activation in COVID-19 is two-fold.

First, SARS-CoV-2 is known to utilize ACE2 as an entry point to certain cell types including those of lung, kidney, brain, and intestinal origin. This leads to reduced levels of ACE2 systemically and higher levels of angiotensin II in comparison with angiotensin 1-7 [12, 13] . This imbalance can lead to reactive oxygen species in the endothelium and vasoconstriction, these in turn promote complement activation and thrombosis [14, 15] . A second proposed mechanism lies in the activation of the MBL pathway by the glycosylated SARS-CoV-2 spike protein. Both of these mechanisms may be shared by the original SARS-CoV virus [16] [17] [18] [19] . Jettisoned viral capsid microparticles that include the spike glycoprotein in the circulation can be endocytosed by ACE2+ endothelia that could result in complement activation via MBL activation without implying viral replication [20] [21] [22] . Second, there may be viremia inducing systemic MASP2-driven thrombosis and complement deposition by cleaving C4 and C2 [20, 23] , as suggested by the detection of coronavirus RNA in the plasma during SARS-CoV [24, 25] .

In this study, an association between cutaneous and subcutaneous microvascular complement deposition reflective of complement activation and SARS CoV-2 docked protein within the endothelium was demonstrated. There was no evidence of viral replication in any of the skin samples studied based on the lack of viral RNA as detected by an ultrasensitive in situ method which the manufacturer indicates can detect 1 SARS-CoV-2 genome per cell [9] . The data suggest that the subcutaneous fat of the skin may define an important site for endocytosed viral proteins since ACE2 was markedly expressed in the skin vasculature of the deeper dermis and subcutaneous fat. Thus, the findings of microvascular injury in apparently normal fat would therefore not be unexpected and provides credence to the pathophysiologic specificity of the complement deposition. Obesity is a risk factor for severe COVID-19 although the exact link between obesity and the severity of disease has not been established. The significant degree of ACE2 expression in subcutaneous vessels allowing the docking of viral proteins could play a role in this association since the number of such microvessels would be in direct proportion to the amount of subcutaneous fat [28] .

Existing data would suggest that the expansion of subcutaneous fat in adults is associated with a pro-angiogenic gene expression profile. Both capillary density and the ability of the subcutaneous fat to produce new capillaries appears to be linked with higher levels of vascular endothelial cell growth factor in non-diabetic obese individuals. Therefore, not only is the overall amount of fat increased but the number of vessels per gram of fat is increased and therefore the fat in an obese patient with severe COVID-19 is potentially a significant fuel for amplification of complement and coagulation pathways due to the quantitative extent of complement activation [29] . Further studies beyond the scope of this paper are needed to evaluate this possibility.

A critical downstream effect of extensive complement activation is the release of other factors that could lead to a systemic increase in coagulopathic events as evidenced by the presence of widespread multiorgan thrombosis and massively elevated D-dimers. For instance, both complement J o u r n a l P r e -p r o o f anaphlatoxins, C3a and C5a, in the complement system can activate platelets and increase the production of tissue factor, respectively [30] [31] [32] . For example, MASP2 is thrombin generating [33] .

Further, as complement destroys the endothelium, procoagulant von Willebrand Factor and FVIII are released, sometimes in high amounts [34, 35] . Interestingly, von Willebrand factor activity is dictated by blood type, with type AB having ~125% activity and type O having ~75% of A and B blood type, which might explain recent reports linking type O blood to better outcomes [36] . This is only part of the interplay, for reciprocally, thrombin, FXa, and FIXa can act to trigger the complement cascade by acting as C3 and C5 convertases [32, 37] . In addition, the alternative pathway is activated by components of complement activation contributing to the distant microvascular injury that occurs. The loss of ACE2 contributes to this prothrombotic state by creating an outsized angiotensin II to angiotensin 1-7 ratio. This leads to clot-fostering vasoconstriction as well as prothrombotic oxidation through Nox-2 [38, 39] . Taken together, COVID-19 is a strongly prothrombotic disease.

The deltoid biopsy area is the recommended preferred site for a skin biopsy in evaluating for evidence of systemic complement activation to reduce the incidence of false positivity for complement deposition. In particular, sun exposure is an independent activator of the complement pathway especially in the setting of photosensitizing agents, and hence sun-exposed biopsy sites are not desirable [40] . Lower extremity biopsies are also not ideal due to the role of hydrostatic pressure in trapping of immune complexes which may result in subclinical classic complement pathway activation [41] .

In summary, the skin represents a potentially important site for complement activation due to released viral proteins binding to cutaneous and subcutaneous ACE2 positive vessels. Additional studies are needed to determine if this viral induced process in the skin is a major factor in the hypercoagulable state and cytokine storm that defines severe COVID-19. In this post mortem normal deltoid skin biopsy, perieccrine blood vessels shows expression of both C4d and spike glycoprotein. Using the NUANCE software, the C4d exhibits a green immunoreactant staining pattern while the spike glycoprotein is red. The co-localized C4d and the SARS CoV-2 spike glycoprotein produce a yellow signal (C4d is stained with DAB while the spike glycoprotein is stained with a red chromagen, 400x) Intraluminal thrombus formation was identified involving rare vessels and in the deeper dermis and subcutaneous fat either attributable to endothelial cell injury or reflective of a procoagulant state which is also operational in these patients (panels B and C). 

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The differing pathophysiologies that underlie COVID 19 associated perniosis and thrombotic retiform purpura: a case series

Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome

The use of C3d and C4d immunohistochemistry on formalin-fixed tissue as a diagnostic adjunct in the assessment of inflammatory skin disease

Cutaneous vascular deposition of C5b-9 and its role as a diagnostic adjunct in the setting of diabetes mellitus and porphyria cutanea tarda

Situ Molecular Pathology and Co-Expression Analyses

Cellular context in epigenetics: Quantitative multicolor imaging and automated per-cell analysis of miRNAs and their putative targets

COVID-19 Complicated by Acute Pulmonary Embolism. Radiol Cardiothorac Imaging

Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx

False-positive results in diagnostic immunohistochemistry are related to horseradish peroxidase conjugates in commercially available assays

Complement activation in angiotensin II-induced organ damage

Complement activation after oxidative stress: Role of the lectin complement pathway

Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Endothelial microparticles and systemic complement activation in patients with chronic kidney disease

Endothelial microparticles activate endothelial cells to facilitate the inflammatory response

The many faces of endothelial microparticles

The role of mannose-binding lectin in health and disease

Detection of severe acute respiratory syndrome coronavirus RNA in plasma during the course of infection

Degos disease: A C5b-9/interferon-a-mediated endotheliopathy syndrome

Visualization of putative coronavirus in kidney

Caution in Identifying Coronaviruses by Electron Microscopy

Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring) 2020

Adipose tissue angiogenesis: Impact on obesity and type-2 diabetes

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development

Links Between Complement Activation and Thrombosis

Complement and Coagulation Systems Molecular Intercommunication between the

Simultaneous activation of complement and coagulation by MBL-associated serine protease 2

von Willebrand factor, endothelial cell damage and atherosclerosis

Markers of endothelial damage in organ dysfunction and sepsis

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Complement and platelets: Mutual interference in the immune network

Vascular superoxide dismutase deficiency impairs endothelial vasodilator function through direct inactivation of nitric oxide and increased lipid peroxidation

Tissue Factor, Blood Coagulation, and Beyond: An Overview

Complement Activation in Inflammatory Skin Diseases

High Hydrostatic Pressure Effect on Activity of Circulating Immune Complex Formation in Blood Serum